SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Serocorrelates of protection against infant group B streptococcus disease

Le Doare, K; Kampmann, B; Vekemans, J; Heath, P; Goldblatt, D; Nahm, MH; Baker, C; Edwards, MS; Kwatra, G; Andrews, N; et al. Le Doare, K; Kampmann, B; Vekemans, J; Heath, P; Goldblatt, D; Nahm, MH; Baker, C; Edwards, MS; Kwatra, G; Andrews, N; Madhi, SA; Meulen, AS-T; Anderson, AS; Corsaro, B; Fischer, P; Gorringe, A (2019) Serocorrelates of protection against infant group B streptococcus disease. LANCET INFECTIOUS DISEASES. ISSN 1473-3099 https://doi.org/10.1016/S1473-3099(18)30659-5
SGUL Authors: Le Doare, Kirsty Le Doare, Kirsty

[img] Microsoft Word (.docx) Accepted Version
Restricted to Repository staff only until 22 July 2019.
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (288kB)

Abstract

Group B streptococcus (GBS) is a leading cause of young infant mortality and morbidity globally, with vaccines being developed for over four decades but none licensed to date. A serocorrelate of protection against invasive disease in young infants is being considered to facilitate vaccine early licensure, followed by demonstration of efficacy assessed postlicensure. In this Review, we synthesise the available scientific evidence to define an immune correlate associated with GBS disease risk reduction on the basis of studies of natural infection. We summarise studies that have investigated GBS serum anticapsular or anti-protein antibodies, and studies measuring the association between antibody function and disease risk reduction. We highlight how knowledge on the development of correlates of protection from existing vaccines could be harnessed to facilitate GBS vaccine development. These lessons include aggregation of serocorrelates of protection for individual serotypes, understanding the relationship between immunity derived from natural exposure of adults and vaccine-induced immunity, or using extrapolation of protection from in-vitro immunoassay results. We also highlight key considerations for the assessment of the role of antibodies to derive a serocorrelate of risk reduction in future seroepidemiological studies of GBS disease.

Item Type: Article
Additional Information: © 2019. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
Keywords: 1103 Clinical Sciences, 1108 Medical Microbiology, Microbiology
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: LANCET INFECTIOUS DISEASES
ISSN: 1473-3099
Dates:
DateEvent
22 January 2019Published Online
24 October 2018Accepted
Publisher License: Creative Commons: Attribution-Noncommercial-No Derivative Works 4.0
Projects:
Project IDFunderFunder ID
OPP1119788Bill and Melinda Gates Foundationhttp://dx.doi.org/10.13039/100000865
URI: http://openaccess.sgul.ac.uk/id/eprint/110201
Publisher's version: https://doi.org/10.1016/S1473-3099(18)30659-5

Actions (login required)

Edit Item Edit Item